NxStage Medical, Inc. (NXTM) Reports In-Line Q3 EPS, Updates Q4 and FY11 Guidance
Tweet
Share
E-mailGet Alerts NXTM Hot Sheet
Join SI Premium – FREE
NxStage Medical, Inc. (NASDAQ: NXTM) reported Q3 EPS of ($0.10), in-line with the analyst estimate of ($0.10). Revenue for the quarter came in at $55.9 million versus the consensus estimate of $53.87 million.
NxStage Medical, Inc. sees Q4 2011 EPS of $-0.10-$-0.08, versus the consensus of $-0.09. NxStage Medical, Inc. sees Q4 2011 revenue of $55.5-$56.5 million, versus the consensus of $56.2 million.
NxStage Medical, Inc. sees FY2011 EPS of $-0.43-$-0.36, versus the consensus of $-0.40. NxStage Medical, Inc. sees FY2011 revenue of $216-$217 million, versus prior guidance of $210-$215 million and the consensus of $214.39 million.
NxStage Medical, Inc. sees Q4 2011 EPS of $-0.10-$-0.08, versus the consensus of $-0.09. NxStage Medical, Inc. sees Q4 2011 revenue of $55.5-$56.5 million, versus the consensus of $56.2 million.
NxStage Medical, Inc. sees FY2011 EPS of $-0.43-$-0.36, versus the consensus of $-0.40. NxStage Medical, Inc. sees FY2011 revenue of $216-$217 million, versus prior guidance of $210-$215 million and the consensus of $214.39 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- South Plains Financial Inc. (SPFI) Tops Q1 EPS by 6c
- Employers Holdings (EIG) Misses Q1 EPS by 2c
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
